We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+24.79%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$1.9B
AUM Growth
+$119M
Cap. Flow
+$19.1M
Cap. Flow %
1.01%
Top 10 Hldgs %
50.01%
Holding
78
New
5
Increased
8
Reduced
9
Closed
7

Top Buys

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$23.9M
2
GERN icon
Geron
GERN
+$18.1M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$17.6M
4
FATE icon
Fate Therapeutics
FATE
+$16.9M
5
APLS
Apellis Pharmaceuticals
APLS
+$14.4M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$22.1M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$20.7M
3
BPMC
Blueprint Medicines
BPMC
+$18.1M
4
VERU icon
Veru
VERU
+$17.7M
5
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
+$8.25M

Sector Composition

Rank Sector Weight
1 Healthcare 99.67%
2 Financials 0.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TSVT
51
DELISTED
2seventy bio
TSVT
$4.31M 0.23%
459,836
– –
RNAC icon
52
Cartesian Therapeutics
RNAC
$229M
$3.71M 0.2%
109,469
– –
BDTX icon
53
Black Diamond Therapeutics
BDTX
$96.8M
$3.63M 0.19%
2,014,858
– –
KNTE
54
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$3.11M 0.16%
510,000
-1,012,559
-67% -$8.25M
MIST icon
55
Milestone Pharmaceuticals
MIST
$138M
$2.77M 0.15%
698,861
– –
NGM
56
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$2.51M 0.13%
500,000
– –
OBIO icon
57
Orchestra BioMed
OBIO
$238M
$2.5M 0.13%
250,000
-150,000
-38% -$1.49M
EQRX
58
DELISTED
EQRx, Inc. Common Stock
EQRX
$2.46M 0.13%
1,000,000
– –
THRD
59
DELISTED
Third Harmonic Bio
THRD
$2.45M 0.13%
570,417
– –
DBVT
60
DBV Technologies
DBVT
$799M
$2.22M 0.12%
145,000
-68,460
-32% -$1.01M
THRX
61
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$2.07M 0.11%
415,000
-477,057
-53% -$2.79M
VERU icon
62
Veru
VERU
$36M
$1.83M 0.1%
34,730
-215,270
-86% -$17.7M
BCEL
63
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$1.76M 0.09%
2,202,333
– –
MREO
64
Mereo BioPharma
MREO
$54.7M
$1.69M 0.09%
2,250,000
– –
TCRT icon
65
Alaunos Therapeutics
TCRT
$4.59M
$974K 0.05%
10,000
– –
LITS
66
Lite Strategy Inc
LITS
$32.8M
$710K 0.04%
145,655
– –
TARA icon
67
Protara Therapeutics
TARA
$220M
$561K 0.03%
209,227
– –
IRON icon
68
Disc Medicine
IRON
$2.94B
$176K 0.01%
130,000
+86,667
+200% +$4.32M
BLCM
69
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$41K ﹤0.01%
56,950
– –
NUVB.WS
70
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$38.5K ﹤0.01%
266,666
– –
SRZNW icon
71
Surrozen Inc Warrant
SRZNW
$69.7K
$4.39K ﹤0.01%
66,666
– –
ACAD icon
72
Acadia Pharmaceuticals
ACAD
$4.43B
– –
-1,263,930
Closed -$20.7M
ALT icon
73
Altimmune
ALT
$552M
– –
-500,000
Closed -$6.38M
BPMC
74
DELISTED
Blueprint Medicines
BPMC
– –
-275,000
Closed -$18.1M
SRPT icon
75
Sarepta Therapeutics
SRPT
$1.57B
– –
-200,000
Closed -$22.1M
1 2
3
4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q4 2022 Portfolio in Review

As of Q4 2022, Boxer Capital held 78 positions worth $1.9B, up 6.7% from $1.78B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Boxer Capital's Q4 2022 filing shows 5 new, 8 increased, 9 reduced and 7 closed positions. Its largest new stake was Axsome Therapeutics: 400,000 shares worth $30.9M. The largest sale was Sarepta Therapeutics, an estimated $22.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Financials.

  • Boxer Capital's largest Q4 2022 buy was Axsome Therapeutics: 400,000 shares worth $30.9M.
  • Boxer Capital added most to Fate Therapeutics in Q4 2022, an estimated $16.9M increase.
  • Boxer Capital's biggest Q4 2022 reduction was Veru, cutting an estimated $17.7M.
  • Boxer Capital fully exited Sarepta Therapeutics in Q4 2022, selling an estimated $22.1M.
  • Boxer Capital's ten largest holdings make up 50% of its $1.9B portfolio in Q4 2022.
  • Boxer Capital opened 5 new positions and closed 7 in Q4 2022.
  • Boxer Capital's portfolio value rose 6.7% quarter-over-quarter to $1.9B.

Based on Boxer Capital's 13F filing for Q4 2022, filed 14 Feb 2023.